Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,31468659,area under the plasma-concentration-time curve (AUC0-24 ),Patients using clopidogrel had a mean predicted area under the plasma-concentration-time curve (AUC0-24 ) of 174.7 ng h/mL (SD: ±112.9 ng h/mL) versus 142.2 ng h/mL (SD: ±92.6 ng h/mL) in patients without clopidogrel.,Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468659/),[h·ng] / [ml],174.7,24233,DB08915,Aleglitazar
,31468659,area under the plasma-concentration-time curve (AUC0-24 ),Patients using clopidogrel had a mean predicted area under the plasma-concentration-time curve (AUC0-24 ) of 174.7 ng h/mL (SD: ±112.9 ng h/mL) versus 142.2 ng h/mL (SD: ±92.6 ng h/mL) in patients without clopidogrel.,Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31468659/),[h·ng] / [ml],142.2,24234,DB08915,Aleglitazar
,22244809,Recovery of total radioactivity,"Recovery of total radioactivity, as a percentage of the dose administered, was high (93 [3]%).","Metabolism, excretion, and pharmacokinetics of [14c]-radiolabeled aleglitazar: a phase I, nonrandomized, open-label, single-center, single-dose study in healthy male volunteers. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22244809/),%,93,273839,DB08915,Aleglitazar
